{"organizations": [], "uuid": "bc12919b0ac4abb0b0a68055191567029acd588a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180329.html", "section_title": "Archive News &amp; Video for Thursday, 29 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-onxeo-fy-recurring-operating-loss/brief-onxeo-fy-recurring-operating-loss-narrows-to-eur-19-2-million-idUSW8N1KI00J", "country": "US", "domain_rank": 408, "title": "Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.581, "site_type": "news", "published": "2018-03-30T00:33:00.000+03:00", "replies_count": 0, "uuid": "bc12919b0ac4abb0b0a68055191567029acd588a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-onxeo-fy-recurring-operating-loss/brief-onxeo-fy-recurring-operating-loss-narrows-to-eur-19-2-million-idUSW8N1KI00J", "ord_in_thread": 0, "title": "Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million", "locations": [], "entities": {"persons": [{"name": "onxeo", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29 (Reuters) - ONXEO SA:\n* FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR AGO\n* FY RECURRING OPERATING LOSS EUR 19.2‍​ MILLION VERSUS LOSS OF EUR 23.2 MILLION YEAR AGO\n* FY NET LOSS EUR 59.1‍​ MILLION VERSUS LOSS OF EUR 22.7 MILLION YEAR AGO\n* END-DEC. CASH POSITION OF EUR 14.3 MILLION, COVERING CURRENT PROGRAMME UNTIL MID-2019\n* LAUNCH OF PRECLINICAL STUDIES WITH FIRST MOLECULE GENERATED BY PLATON EXPECTED BEFORE END-2018\n* RESULTS OF STUDY ON COMBINATION OF BELINOSTAT AND ASIDNA TO BE PRESENTED AT 2018 AACR CONGRESS\n* RESULTS OF SECOND PHASE I CLINICAL STUDY WITH ASIDNA, DRIIV, EXPECTED BEFORE YEAR-END\n* SAYS MIGHT BE ABLE TO LAUNCH CLINICAL TRIAL WITH BELINOSTAT AND ASIDNA COMBINATION IN 2018 Source text: bit.ly/2GWPAfS Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://bit.ly/2GWPAfS", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-30T00:33:00.000+03:00", "crawled": "2018-03-30T12:45:57.049+03:00", "highlightTitle": ""}